A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
A Phase 2, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Solution 5%, Minoxidil Solution 5%, and Vehicle Solution, Applied Twice-daily for 26 Weeks in Males With Androgenetic Alopecia (AGA)
In the register
The register attaches this trial to Clascoterone (Breezula) (Cosmo Pharmaceuticals), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 2
- Sponsor
- Intrepid Therapeutics, Inc.
- Participants (registry)
- 95
- Start
- October 2014
- Primary completion
- December 2015
- Study completion
- May 2016
- Last registry update
- March 2017
- Countries
- United States
Conditions studied: Androgenetic Alopecia
Interventions: CB-03-01 solution, cortexolone 17α-propionate, Minoxidil Solution 5%, Placebo solution
Other trials of Clascoterone (Breezula)
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.